| Name | Title | Contact Details |
|---|
Vein 360 Specializes in reprocessing Closurefast Ablation Catheters. The Vein 360 team is dedicated to providing cost effective reprocessing services.
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.
Berkeley Premium Nutraceuticals currently offers six supplements to address issues including sexual health, fatigue, night vision, and cardiovascular health. The Company is also investigating new formulas to assist with other concerns, including prostate
Blue Sky Broadcast is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kinect is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.